Jane Street’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $600M | Sell |
4,698,800
-1,788,600
| -28% | -$223M | 0.08% | 165 |
|
|
2025
Q4 | $791M | Buy |
6,487,400
+2,709,200
| +72% | +$311M | 0.12% | 113 |
|
|
2025
Q3 | $379M | Sell |
3,778,200
-98,200
| -3% | -$8.84M | 0.06% | 220 |
|
|
2025
Q2 | $321M | Sell |
3,876,400
-189,100
| -5% | -$15.1M | 0.06% | 192 |
|
|
2025
Q1 | $330M | Sell |
4,065,500
-1,546,400
| -28% | -$138M | 0.08% | 152 |
|
|
2024
Q4 | $505M | Buy |
5,611,900
+1,415,800
| +34% | +$137M | 0.11% | 99 |
|
|
2024
Q3 | $415M | Buy |
+4,196,100
| New | +$412M | 0.09% | 111 |
|
|
2022
Q2 | – | Sell |
-2,639,400
| Closed | -$237M | – | 11058 |
|
|
2022
Q1 | $237M | Buy |
2,639,400
+480,600
| +22% | +$44.4M | 0.08% | 156 |
|
|
2021
Q4 | $242M | Buy |
2,158,800
+691,600
| +47% | +$83.4M | 0.08% | 149 |
|
|
2021
Q3 | $184M | Buy |
1,467,200
+535,900
| +58% | +$69M | 0.07% | 189 |
|
|
2021
Q2 | $126M | Sell |
931,300
-943,800
| -50% | -$124M | 0.05% | 263 |
|
|
2021
Q1 | $254M | Buy |
1,875,100
+173,200
| +10% | +$25.9M | 0.13% | 103 |
|
|
2020
Q4 | $240M | Buy |
1,701,900
+45,900
| +3% | +$5.88M | 0.12% | 100 |
|
|
2020
Q3 | $185M | Sell |
1,656,000
-143,600
| -8% | -$16.1M | 0.11% | 116 |
|
|
2020
Q2 | $201M | Buy |
1,799,600
+738,900
| +70% | +$72.8M | 0.15% | 83 |
|
|
2020
Q1 | $82.1M | Buy |
1,060,700
+199,700
| +23% | +$17.7M | 0.08% | 160 |
|
|
2019
Q4 | $81.9M | Buy |
861,000
+185,300
| +27% | +$16M | 0.11% | 117 |
|
|
2019
Q3 | $51.5M | Sell |
675,700
-24,900
| -4% | -$2.07M | 0.09% | 169 |
|
|
2019
Q2 | $61.5M | Sell |
700,600
-341,600
| -33% | -$29.1M | 0.11% | 132 |
|
|
2019
Q1 | $94.4M | Sell |
1,042,200
-2,620,000
| -72% | -$223M | 0.15% | 89 |
|
|
2018
Q4 | $263M | Buy |
3,662,200
+1,387,600
| +61% | +$112M | 0.55% | 27 |
|
|
2018
Q3 | $218M | Buy |
2,274,600
+1,389,400
| +157% | +$135M | 0.43% | 37 |
|
|
2018
Q2 | $84.3M | Sell |
885,200
-489,900
| -36% | -$45M | 0.2% | 66 |
|
|
2018
Q1 | $121M | Buy |
1,375,100
+280,400
| +26% | +$25.6M | 0.31% | 53 |
|
|
2017
Q4 | $92.9M | Sell |
1,094,700
-111,900
| -9% | -$9.37M | 0.27% | 61 |
|
|
2017
Q3 | $104M | Buy |
1,206,600
+780,100
| +183% | +$62.5M | 0.34% | 52 |
|
|
2017
Q2 | $32.9M | Sell |
426,500
-96,200
| -18% | -$6.82M | 0.12% | 157 |
|
|
2017
Q1 | $36.2M | Sell |
522,700
-190,700
| -27% | -$12.8M | 0.16% | 113 |
|
|
2016
Q4 | $42.2M | Sell |
713,400
-815,000
| -53% | -$50.3M | 0.18% | 92 |
|
|
2016
Q3 | $101M | Sell |
1,528,400
-250,100
| -14% | -$15.5M | 0.49% | 37 |
|
|
2016
Q2 | $96.2M | Sell |
1,778,500
-25,900
| -1% | -$1.42M | 0.48% | 36 |
|
|
2016
Q1 | $93.2M | Sell |
1,804,400
-44,700
| -2% | -$2.32M | 0.52% | 28 |
|
|
2015
Q4 | $130M | Sell |
1,849,100
-987,300
| -35% | -$67.3M | 0.81% | 16 |
|
|
2015
Q3 | $177M | Buy |
2,836,400
+728,600
| +35% | +$57.4M | 1.11% | 11 |
|
|
2015
Q2 | $177M | Buy |
2,107,800
+1,864,500
| +766% | +$145M | 1.15% | 12 |
|
|
2015
Q1 | $18.3M | Buy |
243,300
+181,800
| +296% | +$12.7M | 0.14% | 119 |
|
|
2014
Q4 | $3.82M | Buy |
+61,500
| New | +$3.51M | 0.03% | 421 |
|
|
2014
Q3 | – | Sell |
-33,000
| Closed | -$1.69M | – | 3134 |
|
|
2014
Q2 | $1.69M | Buy |
33,000
+15,300
| +86% | +$690K | 0.02% | 616 |
|
|
2014
Q1 | $841K | Buy |
+17,700
| New | +$906K | 0.01% | 1104 |
|
Other funds holding XBI
Jane Street's XBI Position: Q1 2026 in Review
Jane Street increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1,190% in Q1 2026, buying an estimated $9.74M and bringing the position to 84,553 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2443.
Jane Street first reported a position in XBI in Q3 2013 and has held it in 42 quarters since. The position peaked at $281M in Q4 2021. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Jane Street held 84,553 shares of State Street SPDR S&P Biotech ETF worth $10.8M as of Q1 2026.
- Jane Street bought 77,998 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $9.74M.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2443 holding.
- Jane Street first reported a position in State Street SPDR S&P Biotech ETF in Q3 2013 and has held it in 42 quarters since.
- Jane Street's State Street SPDR S&P Biotech ETF position peaked at $281M in Q4 2021.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.